A targeted endocannabinoid enzyme blocker reduced pain without producing a cannabis-like high
A selective MAGL inhibitor called KML29 reduced inflammatory and nerve pain in mice without causing the typical cannabis-like side effects of sedation, temperature drop, and immobility.
Quick Facts
What This Study Found
Researchers tested KML29, a highly selective inhibitor of the enzyme MAGL (which breaks down the endocannabinoid 2-AG), in mouse models of pain. KML29 completely reversed inflammatory pain and partially reversed nerve injury pain. It also completely prevented stomach bleeding caused by the anti-inflammatory drug diclofenac.
Critically, KML29 did not produce the classic cannabis-like side effects (catalepsy, hypothermia, reduced movement) that limit the use of THC and full cannabinoid receptor agonists. However, repeated high-dose treatment led to tolerance, accompanied by CB1 receptor desensitization.
The compound increased brain 2-AG levels while reducing arachidonic acid levels, without affecting anandamide levels, confirming its selective action on the 2-AG pathway.
Key Numbers
KML29 completely reversed carrageenan-induced mechanical allodynia. Partially reversed sciatic nerve injury allodynia. Completely prevented diclofenac gastric hemorrhages. No catalepsy, hypothermia, or hypomotility observed.
How They Did This
In vivo testing in mice using carrageenan-induced inflammatory pain, sciatic nerve injury neuropathic pain, and diclofenac-induced gastric hemorrhage models. Cannabis-like side effects were assessed through locomotor activity, body temperature, catalepsy, and drug discrimination tests.
Why This Research Matters
Pain management is one of the most promising applications of the endocannabinoid system. Showing that 2-AG elevation via MAGL inhibition can produce pain relief without the psychoactive side effects of THC represents a potential path toward cannabinoid-based painkillers that do not impair daily function.
The Bigger Picture
The endocannabinoid system offers multiple drug targets. Rather than activating cannabinoid receptors directly (like THC), boosting the body's own endocannabinoid 2-AG by blocking its breakdown may provide therapeutic benefits with fewer side effects. This "indirect" approach is a major focus of cannabinoid drug development.
What This Study Doesn't Tell Us
Mouse studies do not directly predict human outcomes. Tolerance developed with repeated high-dose administration, which could limit long-term clinical use. Only acute and short-term dosing protocols were tested.
Questions This Raises
- ?Would MAGL inhibitors work for chronic pain in humans?
- ?Can the tolerance issue be managed with dosing strategies?
- ?Would combining MAGL inhibitors with other approaches provide synergistic pain relief?
Trust & Context
- Key Stat:
- Pain relief achieved without sedation, hypothermia, or immobility
- Evidence Grade:
- Well-designed preclinical study with multiple pain models and side effect assessments, but limited to mice.
- Study Age:
- Published in 2014. MAGL inhibitors continue to be developed for pain.
- Original Title:
- In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.
- Published In:
- British journal of pharmacology, 171(6), 1392-407 (2014)
- Authors:
- Ignatowska-Jankowska, B M, Ghosh, S, Crowe, M S, Kinsey, S G, Niphakis, M J, Abdullah, R A, Tao, Q, O' Neal, S T, Walentiny, D M, Wiley, J L, Cravatt, B F, Lichtman, A H
- Database ID:
- RTHC-00806
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can you get pain relief from the endocannabinoid system without getting high?
This mouse study suggests yes. By blocking the enzyme that breaks down the body's own endocannabinoid 2-AG, researchers achieved pain relief without the sedation and other side effects seen with THC.
What is MAGL?
Monoacylglycerol lipase (MAGL) is the enzyme that breaks down 2-AG, the most abundant endocannabinoid in the brain. Blocking MAGL increases 2-AG levels, activating cannabinoid receptors indirectly rather than with an external drug like THC.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00806APA
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S; Kinsey, S G; Niphakis, M J; Abdullah, R A; Tao, Q; O' Neal, S T; Walentiny, D M; Wiley, J L; Cravatt, B F; Lichtman, A H. (2014). In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.. British journal of pharmacology, 171(6), 1392-407. https://doi.org/10.1111/bph.12298
MLA
Ignatowska-Jankowska, B M, et al. "In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.." British journal of pharmacology, 2014. https://doi.org/10.1111/bph.12298
RethinkTHC
RethinkTHC Research Database. "In vivo characterization of the highly selective monoacylgly..." RTHC-00806. Retrieved from https://rethinkthc.com/research/ignatowska-jankowska-2014-in-vivo-characterization-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.